PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17506588-4 2007 Delapril is a potent antihypertensive ACE inhibitor, and indapamide is a thiazide-like diuretic with additional antihypertensive properties. delapril 0-8 angiotensin I converting enzyme Homo sapiens 38-41 17506588-8 2007 Furthermore, combining an ACE inhibitor and a thiazide-type diuretic has been associated with a decreased risk of stroke and is recommended for patients with cerebrovascular disease, a setting in which the combination of delapril and indapamide has therapeutic potential. delapril 221-229 angiotensin I converting enzyme Homo sapiens 26-29 8877275-1 1996 The open trial was designed to evaluate the effects of long-term antihypertensive treatment with the calcium-channel blocker, manidipine and the angiotensin converting enzyme (ACE) inhibitor, delapril on insulin sensitivity in Japanese non-insulin dependent diabetes mellitus (NIDDM) patients with essential hypertension. delapril 192-200 angiotensin I converting enzyme Homo sapiens 176-179 16740017-1 2006 Delapril/manidipine 30 mg/10 mg is a new oral, once-daily, fixed combination of an ACE inhibitor and a dihydropyridine calcium-channel antagonist for the treatment of essential hypertension. delapril 0-8 angiotensin I converting enzyme Homo sapiens 83-86 15531004-2 2004 There have been few studies comparing the efficacy and tolerability of the new fixed combination of the angiotensin-converting enzyme (ACE) inhibitor delapril 30 mg and the calcium channel antagonist manidipine 10 mg with those of a standard combination of another ACE inhibitor and a diuretic. delapril 150-158 angiotensin I converting enzyme Homo sapiens 104-133 15531004-2 2004 There have been few studies comparing the efficacy and tolerability of the new fixed combination of the angiotensin-converting enzyme (ACE) inhibitor delapril 30 mg and the calcium channel antagonist manidipine 10 mg with those of a standard combination of another ACE inhibitor and a diuretic. delapril 150-158 angiotensin I converting enzyme Homo sapiens 135-138 10670908-8 2000 Taken in sum, these findings suggest that the ACE inhibitor delapril is more beneficial than the Ca antagonist manidipine in the treatment of diabetic renal diseases via mechanisms other than the blood pressure regulation, partly through their different effects on tubular function. delapril 60-68 angiotensin I converting enzyme Homo sapiens 46-49 9493125-14 1997 Both the ACE inhibitor delapril and the AT1 blocker candesartan have shown a beneficial effect on insulin sensitivity, and candesartan appears to restore the M value to normal. delapril 23-31 angiotensin I converting enzyme Homo sapiens 9-12 9129996-5 1997 These results indicate that ACE inhibitors such as captopril, delapril and cilazapril have an inhibitory effect on TNF-alpha production not only in vitro as previously reported, but also in vivo, although relatively high concentrations and large doses were required in this study. delapril 62-70 angiotensin I converting enzyme Homo sapiens 28-31 2009148-7 1991 These results indicate that delapril has the least cough stimulatory effect among these ACE inhibitors, which may be clinically beneficial. delapril 28-36 angiotensin I converting enzyme Homo sapiens 88-91 8593759-5 1995 After 3 months of angiotensin-converting enzyme (ACE) inhibition with oral administration of delapril, blood pressure was significantly reduced in the hypertensives with glucose intolerance (n = 9). delapril 93-101 angiotensin I converting enzyme Homo sapiens 18-47 8593759-5 1995 After 3 months of angiotensin-converting enzyme (ACE) inhibition with oral administration of delapril, blood pressure was significantly reduced in the hypertensives with glucose intolerance (n = 9). delapril 93-101 angiotensin I converting enzyme Homo sapiens 49-52 7778536-4 1995 Due to its greater lipophilicity, delapril has been shown to exert a more effective inhibition of vascular ACE than captopril and enalapril, both in vitro and in vivo. delapril 34-42 angiotensin I converting enzyme Homo sapiens 107-110 7778536-5 1995 The activity of delapril on tissue ACE also lasts longer than on the circulating enzyme. delapril 16-24 angiotensin I converting enzyme Homo sapiens 35-38 2009144-0 1991 Characteristics of a new angiotensin converting enzyme inhibitor: delapril. delapril 66-74 angiotensin I converting enzyme Homo sapiens 25-54 2009144-1 1991 Delapril, a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, which has an indanylglycine moiety differing from the proline moiety of captopril or enalapril, is an esterified prodrug that is converted in vivo to its active metabolites. delapril 0-8 angiotensin I converting enzyme Homo sapiens 26-55 2009144-1 1991 Delapril, a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, which has an indanylglycine moiety differing from the proline moiety of captopril or enalapril, is an esterified prodrug that is converted in vivo to its active metabolites. delapril 0-8 angiotensin I converting enzyme Homo sapiens 57-60 2009144-4 1991 Delapril is a more potent inhibitor of vascular wall ACE activity than enalapril or captopril. delapril 0-8 angiotensin I converting enzyme Homo sapiens 53-56 2009147-2 1991 Delapril, a new angiotensin converting enzyme (ACE) inhibitor discovered in the laboratory of Takeda Chemical Industries, Ltd., is the result of drug design based on the structure-activity relationships of ACE inhibitors. delapril 0-8 angiotensin I converting enzyme Homo sapiens 16-45 2009147-2 1991 Delapril, a new angiotensin converting enzyme (ACE) inhibitor discovered in the laboratory of Takeda Chemical Industries, Ltd., is the result of drug design based on the structure-activity relationships of ACE inhibitors. delapril 0-8 angiotensin I converting enzyme Homo sapiens 47-50 2009147-2 1991 Delapril, a new angiotensin converting enzyme (ACE) inhibitor discovered in the laboratory of Takeda Chemical Industries, Ltd., is the result of drug design based on the structure-activity relationships of ACE inhibitors. delapril 0-8 angiotensin I converting enzyme Homo sapiens 206-209 2009147-12 1991 Data derived from the Japan Study Group on Delapril indicate that this ACE inhibitor has excellent hypotensive effects and a high level of safety. delapril 43-51 angiotensin I converting enzyme Homo sapiens 71-74 2009149-1 1991 The effects of delapril, an angiotensin converting enzyme (ACE) inhibitor, on renal function and the renin-angiotensin and kallikrein-prostaglandin systems were investigated in 10 hypertensive patients who were treated for between 4 months and 1 year. delapril 15-23 angiotensin I converting enzyme Homo sapiens 59-62 3345615-0 1988 Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects. delapril 69-77 angiotensin I converting enzyme Homo sapiens 26-57 2177631-1 1990 The antihypertensive effects and pharmacokinetic properties of delapril, an angiotensin-converting enzyme (ACE) inhibitor, were investigated in hypertensive patients with normal renal function (NRF; n = 6) and in those with impaired renal function (IRF; n = 5). delapril 63-71 angiotensin I converting enzyme Homo sapiens 76-105 2177631-1 1990 The antihypertensive effects and pharmacokinetic properties of delapril, an angiotensin-converting enzyme (ACE) inhibitor, were investigated in hypertensive patients with normal renal function (NRF; n = 6) and in those with impaired renal function (IRF; n = 5). delapril 63-71 angiotensin I converting enzyme Homo sapiens 107-110 2177631-5 1990 ACE activity was suppressed from 1 hour after the first dose to 24 hours after the last dose of delapril in both the NRF and IRF groups. delapril 96-104 angiotensin I converting enzyme Homo sapiens 0-3